LRRK2 and Parkinson disease: Similarly, in a multitracer PET study undertaken by Wyle and colleagues, DAT binding in LRRK2 mutation carriers without PD was significantly lower than in healthy controls even in younger age groups, by contrast with findings of 18F-FDOPA uptake which was preserved until age 70 years [163].